Importer of Controlled Substances; Notice of Registration; GE Healthcare, 23595 [2013-09290]

Download as PDF 23595 Federal Register / Vol. 78, No. 76 / Friday, April 19, 2013 / Notices The import of the above listed basic classes of controlled substances will be granted only for analytical testing and clinical trials. This authorization does not extend to the import of a finished FDA approved or non-approved dosage forms for commercial distribution in the United States. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule II, which falls under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 20, 2013. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic classes of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: April 10, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. mstockstill on DSK4VPTVN1PROD with NOTICES BILLING CODE 4410–09–P Importer of Controlled Substances; Notice of Registration DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration; GE Healthcare By Notice dated January 31, 2013, and published in the Federal Register on February 6, 2013, 78 FR 8583, GE Healthcare, 3350 North Ridge Avenue, Jkt 229001 [FR Doc. 2013–09290 Filed 4–18–13; 8:45 am] Drug Enforcement Administration BILLING CODE 4410–09–P 17:11 Apr 18, 2013 Dated: April 10, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. DEPARTMENT OF JUSTICE [FR Doc. 2013–09302 Filed 4–18–13; 8:45 am] VerDate Mar<15>2010 Arlington Heights, Illinois 60004–1412, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Cocaine (9041), a basic class of controlled substance listed in schedule II. The company plans to import small quantities of ioflupane, in the form of three separate analogues of Cocaine, to validate production and quality control systems, for a reference standard, and for producing material for a future investigational new drug (IND) submission. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of GE Healthcare to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated GE Healthcare to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. By Notice dated January 16, 2013, and published in the Federal Register on January 25, 2013, 78 FR 5497, Nebraska State Penitentiary, 4201 South 14th Street, Lincoln, Nebraska 68502, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of Pentobarbital (2270), a basic class of controlled substance listed in schedule II. The facility intends to import the above listed controlled substance for legitimate use. Supplies of this PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 particular controlled substance are inadequate and are not available in the form needed within the current domestic supply of the United States. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Nebraska State Penitentiary to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Nebraska State Penitentiary to ensure that its registration is consistent with the public interest. The investigation has included inspection and testing of the Nebraska State Penitentiary facility’s physical security systems, verification of its compliance with state and local laws, and a review of its background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named facility is granted registration as an importer of the basic class of controlled substance listed. Dated: April 11, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–09299 Filed 4–18–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Penick Corporaton Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 1, 2013, Penick Corporation, 33 Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Morphine (9300) ........................... Oripavine (9330) ........................... Thebaine (9333) ........................... E:\FR\FM\19APN1.SGM 19APN1 Schedule II II II II II II II II II II

Agencies

[Federal Register Volume 78, Number 76 (Friday, April 19, 2013)]
[Notices]
[Page 23595]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-09290]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Registration; GE 
Healthcare

    By Notice dated January 31, 2013, and published in the Federal 
Register on February 6, 2013, 78 FR 8583, GE Healthcare, 3350 North 
Ridge Avenue, Arlington Heights, Illinois 60004-1412, made application 
by renewal to the Drug Enforcement Administration (DEA) to be 
registered as an importer of Cocaine (9041), a basic class of 
controlled substance listed in schedule II.
    The company plans to import small quantities of ioflupane, in the 
form of three separate analogues of Cocaine, to validate production and 
quality control systems, for a reference standard, and for producing 
material for a future investigational new drug (IND) submission.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and 952(a) and determined that the 
registration of GE Healthcare to import the basic class of controlled 
substance is consistent with the public interest and with United States 
obligations under international treaties, conventions, or protocols in 
effect on May 1, 1971. DEA has investigated GE Healthcare to ensure 
that the company's registration is consistent with the public interest. 
The investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above named company is granted 
registration as an importer of the basic class of controlled substance 
listed.

    Dated: April 10, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-09290 Filed 4-18-13; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.